2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 958

Serum Cytokine Changes In Rituximab-Treated Rheumatoid Arthritis Patients
Abstract Number: 1869

Serum Cytokine/Chemokine Profiles Are Useful For Evaluating Pathological Conditions Of Rheumatoid Arthritis and Diagnosing Anti-CCP Antibody-Negative Patients
Abstract Number: 1995

Serum Homocysteine Related To Decreased Renal Function In Chronic Gouty Patients
Abstract Number: 868

Serum Immunoglobulin Free Light Chains and Rheumatoid Arthritis: A Population-Based Study
Abstract Number: 2079

Serum Interferon α, β and Interleukin-18 Are Associated With Disease Activity Of Rapidly Progressive Interstitial Lung Disease In Patients With Clinical Amyopathic Dermatomyositis
Abstract Number: 2069

Serum Interferon-α Is a Biomarker To Reflect The Disease Activity In Patients With Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) Antibody-Positive Dermatomyositis
Abstract Number: 787

Serum Leucine-Rich Alpha-2 Glycoprotein As a Marker For Disease Activity In Adult-Onset Still’s Disease
Abstract Number: 2491

Serum Levels Of Novel Noggin- and Sclerostin-Immune Complexes Are Elevated In Ankylosing Spondylitis
Abstract Number: 1293

Serum Matrix Metalloproteinase 13 As a Translational Marker For Efficacy Of Anti-Arthritic Treatments In Rat Collagen Induced Arthritis and Mouse Model Of Lipopolysaccharide-Induced Bone Resorption
Abstract Number: 2544

Serum Mediated Phagocytosis Of Necrotic Material By Polymorphonuclear Leukocytes May Be Used As a Tool To Predict Clinical Manifestations In Systemic Lupus Erythematosus
Abstract Number: 2540

Serum Mercury Level and Disease Activity Of Systemic Lupus Erythematosus (SLE): A Case-Control Study
Abstract Number: 2756

Serum Periostin Is Associated With Prevalent Knee Osteoarthritis and Predicts Disease Progression In Women: The Ofely Study
Abstract Number: 1545

Serum Periostin: a New Marker Of Local Bone Formation In Early Inflammatory Back Pain: results From The DESIR Cohort
Abstract Number: 2914

Serum Proteins and Whole Blood Transcripts Suppressed By An Anti-Type I Interferon Receptor Monoclonal Antibody In Subjects With Systemic Sclerosis
Abstract Number: 2569

Serum S100A4 Levels Correlate With Skin Fibrosis and Lung Involvement In Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].